IR@PKUHSC  > 北京大学第二临床医学院  > 眼科
学科主题临床医学
Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion
Tao, Y.1,2; Hou, J.1; Jiang, Y-R1; Li, X-X1; Jonas, J. B.2
关键词Bevacizumab Central Retinal Vein Occlusion Triamcinolone Acetonide
刊名EYE
2010-05-01
DOI10.1038/eye.2009.220
24期:5页:810-815
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Ophthalmology
资助者Beijing Natural Science Foundation, Beijing, China ; Beijing Natural Science Foundation, Beijing, China
研究领域[WOS]Ophthalmology
关键词[WOS]RANDOMIZED CLINICAL-TRIAL ; INTRAOCULAR-PRESSURE ; INJECTION ; MANAGEMENT ; AVASTIN ; SECONDARY ; SAFETY
英文摘要

Purpose To compare the effect of intravitreal bevacizumab vs intravitreal triamcinolone for the treatment of non-ischaemic central retinal vein occlusion (CRVO).

Methods The comparative nonrandomized retrospective clinical interventional study included 72 patients with non-ischaemic CRVO, divided into a bevacizumab group of 30 patients (1.25 mg bevacizumab) and a triamcinolone group of 42 patients (4.0 mg triamcinolone). All patients were consecutively included. At baseline, both study groups did not vary significantly in visual acuity, macular thickness, and duration of symptoms (191 +/- 300 days vs 222 +/- 256 days). The minimal follow-up was 3 months (mean: 7.8 +/- 4.3 months; range:3-12 months). During follow-up, 1.3 +/- 0.4 re-injections of the triamcinolone group (range: 1-2 injections) and 2.7 +/- 1.8 re-injections of bevacizumab (range:1-6 injections) were administered.

Results In both study groups, the mean visual acuity increased significantly (P<0.001) from baseline during follow-up. The differences in gain in visual acuity were not statistically significant (P>0.40) between both study groups at any time during follow-up. The mean macular thickness decreased significantly (P<0.001) in both study groups, with the reduction being significantly (P = 0.006) more pronounced in the triamcinolone group. Intraocular pressure increased significantly (P<0.001) in the triamcinolone group.

Conclusions In long-standing non-ischaemic CRVO, intravitreal bevacizumab and intravitreal triamcinolone are both associated with a comparable gain in visual acuity. The reduction in macular oedema was more marked in the triamcinolone group. In view of the potential complications of intravitreal triamcinolone in terms of intraocular pressure rise and cataractogenesis, bevacizumab may be preferred compared with triamcinolone for intravitreal use in non-ischaemic CRVO. Eye (2010) 24, 810-815; doi:10.1038/eye.2009.220; published online 21 August 2009

语种英语
所属项目编号7062065
资助者Beijing Natural Science Foundation, Beijing, China ; Beijing Natural Science Foundation, Beijing, China
WOS记录号WOS:000277592900010
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54602
专题北京大学第二临床医学院_眼科
作者单位1.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China
2.Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany
推荐引用方式
GB/T 7714
Tao, Y.,Hou, J.,Jiang, Y-R,et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion[J]. EYE,2010,24(5):810-815.
APA Tao, Y.,Hou, J.,Jiang, Y-R,Li, X-X,&Jonas, J. B..(2010).Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.EYE,24(5),810-815.
MLA Tao, Y.,et al."Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion".EYE 24.5(2010):810-815.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tao, Y.]的文章
[Hou, J.]的文章
[Jiang, Y-R]的文章
百度学术
百度学术中相似的文章
[Tao, Y.]的文章
[Hou, J.]的文章
[Jiang, Y-R]的文章
必应学术
必应学术中相似的文章
[Tao, Y.]的文章
[Hou, J.]的文章
[Jiang, Y-R]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。